# Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

Study · id `cardio:ct-nct05488431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05488431](<https://clinicaltrials.gov/study/NCT05488431>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05488431

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 121 participants.

## Technical summary

Registry record NCT05488431. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 121 participants (planned count; ClinicalTrials.gov record NCT05488431, source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)
- Started: 2023-03-01 (actual) (ClinicalTrials.gov record NCT05488431, source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)
- Primary completion: 2028-03-01 (anticipated) (ClinicalTrials.gov record NCT05488431, source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)
- Completion: 2028-03-01 (anticipated) (ClinicalTrials.gov record NCT05488431, source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05488431, source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05488431-2025-12-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
- Condition: Dyslipidemias
- Condition: Cardiovascular Diseases
- Condition: HIV Infections
- Condition: Atherosclerosis
- Intervention (Drug): Bempedoic acid
- Intervention (Other): Placebo
- Lead sponsor: Priscilla Hsue, MD
- Lead sponsor class: OTHER
- Collaborator: University of California, Los Angeles
- Collaborator class: OTHER
- Collaborator: Massachusetts General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry lists this organization as a collaborator: University of California, Los Angeles (`cardio:org-university-of-california-los-angeles`)
- Registry lists this organization as a collaborator: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)

## Provenance

Content hash: 00ef8da46a80d956dc1b1e2b41581cd748cf17917fb8e615c015ac97c0553818
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
